EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients

Rok Seon Choung, Jyoti Ramakrishna, Vivek Pradhan, Brett King, Emma Guttman-Yassky, Elena Peeva, Joseph A Murray

Archives of Dermatological Research · 2025

DOI: 10.1007/s00403-024-03784-6 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Archives of Dermatological Research, 2025. Verfasst von Rok Seon Choung und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Choung.rokson@mayo.edu. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase 3, Protein Kinase Inhibitors, Vitiligo. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Celiac disease (CeD) has shown an association with autoimmune disorders including vitiligo and alopecia areata (AA). Ritlecitinib, a JAK3 and TEC kinase family inhibitor, has been approved for treatment of patients with AA and is in late-stage development for vitiligo. Ritlecitinib inhibits cytotoxic T cells, NK cells, and B cells which play a role in the pathogenesis of CeD.

Objective

We aimed to explore the potential effect of ritlecitinib on CeD serology levels before and after ritlecitinib treatment in research participants of clinical trials.

Methods

The effect of ritlecitinib on CeD serology (tTG-IgA, DGP-IgA/IgG) levels was retrospectively evaluated in participants from three phase 2 and one phase 3 ritlecitinib clinical trials including participants with active AA, rheumatoid arthritis (RA) and vitiligo, whose serum samples at baseline and post-treatment were available. All statistical comparisons of the changes between initial and follow-up samples used the Wilcoxon matched pairs exact test.

Results

Of 1146 research participants, 21 individuals had a positive tTG-IgA in their baseline samples (positivity rate, 0.018, 95% CI = 0.011–0.028). Among these 21 individuals, follow-up samples were available in 15 participants from the ritlecitinib group and in 3 from the placebo group. In follow-up samples, the values of tTG-IgA in the 15 participants treated with ritlecitinib significantly decreased from baseline ( p < 0.01), while in the placebo group the tTGA-IgA levels remained close to the baseline values.

Conclusion

A decrease in CeD serology levels with ritlecitinib treatment suggests that ritlecitinib may provide beneficial effect in CeD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataJanus Kinase 3Protein Kinase InhibitorsVitiligoAdultFemaleHumansMaleMiddle AgedYoung AdultArthritis, RheumatoidAutoimmunityBiomarkersClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicRetrospective StudiesTreatment OutcomeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Alopecia areataCeliac autoimmunityRitlecitinibVitiligo

Substanzen

BiomarkersJAK3 protein, humanJanus Kinase 3Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Choung.rokson@mayo.edu.
  • Division of Gastroenterology and Hepatology, 200 1st Street SW, Rochester, MN, 55905, USA. Choung.rokson@mayo.edu.
  • Inflammation and Immunology Research Unit, Pfizer R&D, Cambridge, MA, USA.
  • Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Division of Gastroenterology and Hepatology, 200 1st Street SW, Rochester, MN, 55905, USA. murray.joseph@mayo.edu.

Zitieren

APA

Choung, R. S., Ramakrishna, J., Pradhan, V., King, B., Guttman-Yassky, E., Peeva, E., & Murray, J. A. (2025). Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients. Archives of Dermatological Research. https://doi.org/10.1007/s00403-024-03784-6

Vancouver

Choung RS, Ramakrishna J, Pradhan V, King B, Guttman-Yassky E, Peeva E, et al. Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients. Archives of Dermatological Research. 2025. doi:10.1007/s00403-024-03784-6

BibTeX
@article{Choung2025,
  author = {Choung, Rok Seon and Ramakrishna, Jyoti and Pradhan, Vivek and King, Brett and Guttman-Yassky, Emma and Peeva, Elena and Murray, Joseph A},
  title = {Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients},
  journal = {Archives of Dermatological Research},
  year = {2025},
  doi = {10.1007/s00403-024-03784-6}
}
Kostenlos starten →